A proprietary, breakthrough technology, the Castling method (LN-Cast) allows manipulation/ engineering of miRNA expression for enhanced efficacy and longevity of cells employed in cell-based therapies (US patent application filed).
ACT involves transfer to a patient, of manipulated cells, either originated from the patient (autologous) or off the shelf (allogenic). The cells are most commonly derived from the immune system (for example T cells) with the goal of improving immune functionality and characteristics. Adoptive T cell-based immunotherapy is used for treating cancer patients.
The process involves isolation of circulating T cells or tumor infiltrating lymphocytes (TIL)] and then engineering the cells to express chimeric antigen receptor (CAR) or T cell receptor (TCR) against specific tumor associated antigens (TAA), then expanding cells and re-injecting them into the patient (Figure 6 [i]).
[i]Z hao Lijun, Cao Yu J., Engineered T Cell Therapy for Cancer in the Clinic, Frontiers in Immunology , VOL 10, 2019,
Page 2250, URL=https://www.frontiersin.org/article/10.3389/fimmu.2019.02250, DOI=10.3389/fimmu.2019.02250 , ISSN=1664-3224